© 2021 MJH Life Sciences and Neurology Live. All rights reserved.
© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
June 08, 2021
Recent data presented at the AHS annual meeting showed clinically meaningful improvements in MMD and MHD in patients with both chronic and episodic migraine.
A post-hoc analysis of 4 clinical trials of galcanezumab found no differences between dose groups of galcanezumab or placebo in rates of ‘wearing off’ effect.
The director of the Headache Center of Southern California provided insight on how a layered treatment approach to chronic migraine can be directly implemented into clinical care.
The director of the Montefiore Headache Center detailed the ways the Migraine Buddy app can help simplify conducting migraine clinical trials while expanding the reach of patients.
Absence of photophobia, phonophobia, and nausea were achieved in a similar percentage of perimenstrual and non-perimenstrual ubrogepant-treated attacks.
June 07, 2021
These real-world findings confirm that a 156- to 195-unit dose of onabotulinumtoxinA is efficacious and safe, consistent with findings from the PREEMPT clinical trials.
The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed the findings of the STOP 301 study.
Using the FDA-approved Cefaly device, the TEAM study data suggest that the device can be applied as a safe alternative to pharmacological treatments in the acute treatment of migraine.
The chief medical officer of Biohaven Pharmaceuticals discussed the findings of an assessment of rimegepant (Nurtec ODT) exposure with concomitant administration of inhibitors of P-gp and BCRP transporters.
June 06, 2021
An assessment of data from the PROMISE-2 trial suggests that individuals who respond to treatment in the first month are likely to maintain their response through at least 6 months.